Incretins and thiazolidinediones in glucose homeostasis and cancer: Role of common polymorphisms

Cancer Letters

Volumn 323, Issue 2, 2012, Pages 128-134

  Arora, Shitij ^a   Mehrotra, Anurag ^a   Gulati, Subhash C ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Oncogenesis; PPAR ; Thiazolidinediones; Transcription factor 7 like 2

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTINEOPLASTIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIPIZIDE; GLUCAGON LIKE PEPTIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INCRETIN; INSULIN; METFORMIN; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR 7 LIKE 2; WNT PROTEIN;

ANTIDIABETIC ACTIVITY; BLADDER CANCER; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; ENZYME ACTIVATION; GENETIC POLYMORPHISM; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RISK REDUCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; THYROID CANCER;

EID: 84863091302     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.04.002     Document Type: Review

References (58)

1. Sherry B., Blanck H., Galuska D., Pan L., Dietz W., Balluz L. Vital signs: state-specific obesity prevalence among adults-United States. MMWR Morb. Mortal. Wkly. Rep. 2010, 59:1-5.
2. Boyle J.P., Thompson T.J., Gregg E.W., Barker L.E., Williamson D.F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence, Popul. Health Metrics 2010, 8:29.
3. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA: Cancer J. Clin. 2010, (CAAC. 20073v1).
4. World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation, 2000, p. 253.
5. Knowler W.C., Pettitt D., Saad M.F., et al. Obesity in the Pima Indians: its magnitude and relationship with diabetes. Am. J. Clin. Nutr. 1991, 53:1543S.
6. Chan J., Cheung J., Stehouwer C., Emeis J., Ko P.C.Y.T., Yudkin J. The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the metabolic syndrome-an analysis by structural equation modelling. Month 2002, 26:994-1008.
7. Yajnik C. Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries. J. Nutr. 2004, 134:205.
8. Yajnik C. Nutritional control of fetal growth. Nutr. Rev. 2006, 64:S50-S51.
9. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N. Engl. J. Med. 2003, 348:1625-1638.
10. Gallagher E.J., LeRoith D. Insulin, insulin resistance, obesity, and cancer. Curr. Diab. Rep. 2010, 10:93-100.
11. McCarthy M.I. Genomics, type 2 diabetes, and obesity. N. Engl. J. Med. 2010, 363:2339-2350.
12. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
13. Drucker D.J. The biology of incretin hormones. Cell Metab. 2006, 3:153-165.
14. Nakazaki M., Crane A., Hu M., Seghers V., Ullrich S., Aguilar-Bryan L., Bryan J. CAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets. Diabetes 2002, 51:3440-3444.
15. Nakazaki M., Crane A., Hu M., Seghers V., Ullrich S., Aguilar-Bryan L., Bryan J. CAMP-activated protein kinase-independent potentiation of insulin secretion by cAMP is impaired in SUR1 null islets. Diabetes 2002, 51:3440-3449.
16. Wang Q., Brubaker P.L. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8week-old db/db mice. Diabetologia 2002, 45:1263-1273.
17. Jarvinen H.Y. Thiazolidinediones. N. Engl. J. Med. 2004, 351:1106-1118.
18. Chou F.S., Wang P.S., Kulp S., et al. Effects of thiazolidinediones on differentiation, proliferation, and apoptosis. Mol. Cancer Res. 2007, 5:523-530.
19. Winder W.W., Hardie D.G. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol. 1999, 277:E1-E10.
20. Lizcano J.M., Goransson O., Toth R., et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004, 23:833-843.
21. Micic D., Cvijovic G., Trajkovic V., Duntas L.H., Polovina S. Metformin: its emerging role in oncology. Hormones (Athens) 2011, 10:5-15.
22. Jensen M., De Meyts P. Molecular mechanisms of differential intracellular signaling from the insulin receptor. Vitam. Horm. 2009, 80:51-75.
23. Zhu W., Shiojima I., Ito Y., et al. IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis. Nature 2008, 454:345-349.
24. The Endogenous Hormones and Breast Cancer Collaborative Group, Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies, Lancet Oncol. 11 (2010) 530-542.
25. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363:1346-1353.
26. Lee S.W., Lee S.Y., Lee S.R., Ju W., Kim S.C. Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia. J. Gynecol. Oncol. 2010, 21:174-180.
27. Grant S.F.A., Thorleifsson G., Reynisdottir I., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 2006, 38:320-323.
28. Helgason A., Pálsson S., Thorleifsson G., et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat. Genet. 2007, 39:218-225.
29. Yi F., Brubaker P.L., Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3. J. Biol. Chem. 2005, 280:1457.
30. Lyssenko V., Lupi R., Marchetti P., et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J. Clin. Invest. 2007, 117:2155.
31. Loder M.K., da Silva X.G., McDonald A., Rutter G.A. TCF7L2 controls insulin gene expression and insulin secretion in mature pancreatic beta-cells. Biochem. Soc. Trans. 2008, 36:357.
32. da Silva X.G., Loder M.K., McDonald A., et al. TCF7L2 regulates late events in insulin secretion from pancreatic islet-cells. Diabetes 2009, 58:894.
33. Korinek V., Barker N., Morin P.J., et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997, 275:1784.
34. Peifer M., Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 2000, 287:1606.
35. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003, 116:1175.
36. Cavallo R.A., Cox R.T., Moline M.M., et al. Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 1998, 385:604-608.
37. Valenta T., Lukas J., Korinek V. HMG box transcription factor TCF 4's interaction with CtBP1 controls the expression of the Wnt target Axin2/Conductin in human embryonic kidney cells. Nucleic Acids Res. 2003, 31:2369.
38. Kim M.S., Kim S.S., Ahn C.H., Yoo N.J., Lee S.H. Frameshift mutations of Wnt pathway genes AXIN2 and TCF7L2 in gastric carcinomas with high microsatellite instability. Hum. Pathol. 2009, 40:58-64.
39. Furuuchi K., Tada M., Yamada H., et al. Somatic mutations of the APC gene in primary breast cancers. Am. J. Pathol. 2000, 156:1997.
40. Oliva E., Sarrio D., Brachtel E., et al. High frequency of catenin mutations in borderline endometrioid tumours of the ovary. J. Pathol. 2006, 208:708-713.
41. Koch A., Weber N., Waha A., et al. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas. J. Pathol. 2004, 204:546-554.
42. Li C.M., Kim C.E., Margolin A.A., et al. CTNNB1 mutations and overexpression of Wnt/{beta}-catenin target genes in WT1-mutant Wilms' tumors. Am. J. Pathol. 2004, 165:1943.
43. Kurashina R., Ohyashiki J.H., Kobayashi C., et al. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via [beta]-catenin/TCF7L2 pathway in adult T cell leukemia cells. Cancer Lett. 2009, 284:62-70.
44. Liu Z., Habener J.F. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J. Biol. Chem. 2008, 283:8723.
45. Koehler J.A., Drucker D.J. Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes 2006, 55:1369.
46. M. Elashoff, A.V. Matveyenko, B. Gier, R. Elashoff, P.C. Butler, Increased incidence of pancreatitis and cancer among patients given glucagon-like peptide-1 based therapy, Gastroenterology (2011).
47. Altshuler D., Hirschhorn J.N., Klannemark M., et al. The common PPAR Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 2000, 26:76-80.
48. Barak Y., Nelson M.C., Ong E.S., et al. PPAR [gamma] is required for placental, cardiac, and adipose tissue development. Mol. Cell 1999, 4:585-595.
49. Kubota N., Terauchi Y., Miki H., et al. PPAR [gamma] mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 1999, 4:597-609.
50. Choi J.H., Banks A.S., Estall J.L., et al. Obesity-linked phosphorylation of PPARγ by cdk5 is a direct target of the anti-diabetic PPARγ ligands. Nature 2010, 466:451-456.
51. Yki-Järvinen H. Thiazolidinediones. N. Engl. J. Med. 2004, 351:1106.
52. Takeuchi S., Okumura T., Motomura W., Nagamine M., Takahashi N., Kohgo Y. Troglitazone induces G1 arrest by p27Kip1 induction that is mediated by inhibition of proteasome in human gastric cancer cells. Cancer Sci. 2002, 93:774-782.
53. Motomura W., Takahashi N., Nagamine M., et al. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int. J. Cancer 2004, 108:41-46.
54. Koga H., Harada M., Ohtsubo M., et al. Troglitazone induces p27Kip1 associated cell cycle arrest through down regulating Skp2 in human hepatoma cells. Hepatology 2003, 37:1086-1096.
55. Motomura W., Tanno S., Takahashi N., et al. Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 2005, 332:89-94.
56. Chang C.H., et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2011 Dec 2, 10.1002/hep. 25509.
57. Lai S.W., et al. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin. Lung Cancer 2012, 13:143-148.
58. Kassouf W., Chintharlapalli S., Abdelrahim M., Nelkin G., Safe S., Kamat A.M. Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res. 2006, 66:412-418.